会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 62. 发明授权
    • Nontoxic extract of Larrea tridentata and method of making same
    • 无毒提取物及其制备方法
    • US5837252A
    • 1998-11-17
    • US726686
    • 1996-10-07
    • Robert A. SinnottW. Dennis ClarkKenneth Frank DeBoer
    • Robert A. SinnottW. Dennis ClarkKenneth Frank DeBoer
    • A23L1/30A61K36/00A61K36/185A61K36/28A61K36/29A61K45/06A61P29/00C07C37/07A01N65/00
    • C07C37/07A23L33/10A23L33/105A61K36/185A61K36/28A61K36/29A61K45/06Y10S514/885Y10S514/886Y10S514/969
    • A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself. Additional amounts of ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamn E may be added to the extract to inhibit the natural oxidation of the NDGA into the toxic NDGA quinone in vivo, or during processing or storage. The resulting extract is useful in the treatment of viral diseases caused by viruses from the Herpesviridae family or viruses which require the Sp1 class of proteins to initiate viral replications. The resulting compound can also be used as an anti-inflammatory when the inflaatory diseases are mediated by the effects of leukotrienes. The listed reducing agents can also be used to stabilize NDGA as a therapeutic agent or a food additive.
    • 具有药理活性的无毒性治疗剂,其包含三氯氰菊酯植物材料和抗坏血酸的浓缩提取物,抗坏血酸酯,抗坏血酸盐,丁基化羟基苯甲醚,丁基化羟基甲苯,硫化氢,次磷酸,一硫代甘油,亚硫酸氢钾,没食子酸丙酯, 亚硫酸氢钠,连二亚硫酸钠,硫代硫酸钠,二氧化硫,亚硫酸,生育酚或维生素E是通过使用有机溶剂,优选丙酮萃取植物材料的方法制备的,然后用列出的一种 还原剂酸降低有毒的NDGA醌,其自然发生在植物材料中,到NDGA本身。 附加量的抗坏血酸,抗坏血酸酯,抗坏血酸盐,丁基化羟基苯甲醚,丁基化羟基甲苯,硫化氢,次磷酸,一硫代甘油,亚硫酸氢钾,没食子酸丙酯,亚硫酸氢钠,连二亚硫酸钠,硫代硫酸钠,二氧化硫,亚硫酸 ,生育酚或维生素E可以加入到提取物中以抑制NDGA在体内或在加工或储存期间自然氧化成有毒的NDGA醌。 所得提取物可用于治疗由疱疹病毒科家族病毒引起的病毒性疾病或需要Sp1类蛋白质启动病毒复制的病毒。 所产生的化合物也可以用作抗炎药物,当炎症疾病由白三烯的作用介导时。 列出的还原剂也可用于稳定NDGA作为治疗剂或食品添加剂。
    • 63. 发明授权
    • Preparation of alkylphenols
    • 烷基酚的制备
    • US5817891A
    • 1998-10-06
    • US715830
    • 1996-09-19
    • Franz Josef BrockerPeter TrubenbachManfred BaumannJurgen Schubert
    • Franz Josef BrockerPeter TrubenbachManfred BaumannJurgen Schubert
    • C07C37/07
    • C07C37/07
    • A process for the preparation of alkylphenols of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 stand for hydrogen or C.sub.1 -C.sub.8 alkyl, by reaction of an alkylcyclohex-2-en-1-one of the formula II ##STR2## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 have the aforementioned meanings, at temperatures of from 200.degree. to 400.degree. C. and pressures ranging from 0.01 to 50 bar in the presence of palladium-on-.alpha.-Al.sub.2 O.sub.3 catalysts, wherein the catalyst used has a specific surface area (BET) of from 1 to 10 m.sup.2 /g, a pore diameter of from 5 nm to 300 .mu.m and a pore volume of from 0.1 to 0.5 cm.sup.3 /g, from 80 to 100% of the pores having a diameter of from 40 to 400 nm, and also novel palladium-on-.alpha.-Al.sub.2 O.sub.3 catalysts as obtained from a fine-grained alumina powder by steps of molding, pyrolysis and calcination.
    • 通过烷基环己-2-烯-1-酮的反应制备式I的烷基酚的方法,其中R 1,R 2,R 3,R 4和R 5代表氢或C 1 -C 8烷基, 其中R 1,R 2,R 3,R 4和R 5具有上述含义的式II(II)中的一种,在200-400℃的温度和0.01至50巴的压力下, 的钯 - α-Al 2 O 3催化剂,其中使用的催化剂具有1至10m 2 / g的比表面积(BET)为1至10m 2 / g,孔径为5nm至300μm,孔体积为0.1至 0.5cm 3 / g,直径为40〜400nm的孔的80〜100%,以及由细晶粒状氧化铝粉末得到的新型钯 - α-Al 2 O 3催化剂,其通过成型,热解和 煅烧。